UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC
20549
________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 13, 2019
BIOSPECIFICS TECHNOLOGIES
CORP.
(Exact Name of Registrant as Specified in
Charter)
Delaware | 001-34236 | 11-3054851 |
(State or Other Jurisdiction | (Commission | (IRS Employer |
of Incorporation) | File Number) | Identification No.) |
35 Wilbur Street | 11563 |
Lynbrook, NY | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: 516.593.7000
N/A
(Former name or former address, if
changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425) .
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12).
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240-14d-2(b)).
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240-13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, Par Value $0.001 | BSTC | Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
INTRODUCTORY COMMENT
Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technologies Corp.
ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
The 2019 annual meeting of stockholders of the Company (the 2019 Annual Meeting) was held on June 13, 2019. Set forth below are the final voting results for each of the matters submitted to a vote of the stockholders of the Company at the 2019 Annual Meeting.
Proposal 1. The stockholders of the Company elected Michael Schamroth to the Board of Directors to serve until the 2022 annual meeting of stockholders or until he resigns, is removed, or otherwise leaves office, based upon the following votes:
Director Name | For | Withheld | Broker Non-Vote |
Michael Schamroth | 2,888,619 | 3,015,752 | 948,211 |
Proposal 2. The stockholders of the Company approved the ratification of the appointment of EisnerAmper LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2019, based upon the following votes:
For | Against | Abstain | Broker Non-Vote |
6,834,804 | 17,556 | 222 | 0 |
Proposal 3. The stockholders of the Company approved the BioSpecifics Technologies Corporation 2019 Omnibus Incentive Compensation Plan, based upon the following votes:
For | Against | Abstain | Broker Non-Vote |
3,321,396 | 2,579,924 | 2,951 | 948,211 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 14, 2019 | BIOSPECIFICS TECHNOLOGIES CORP. |
(Registrant) |
/s/ Dr. Ronald Law | |
Dr. Ronald Law | |
Principal Executive Officer |